KMDAKamada Ltd.Healthcare · Drug Manufacturers - Specialty & Genericas of 2026-09-16
Horizon

Issued 2026-09-16 at $8.19 · now $8.19 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, KMDA has typically landed between $7.15 and $9.67 — a range of −12.7% to +18.1% from the issuance price $8.19.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

3,322 overlapping 1 month windows · 2013-06-032026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($8.19) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where KMDA has typically landed a month from the 2026-09-16 close of $8.19 — the range is history, not a prediction.

$7.15worst · -12.7%$9.67best · +18.1%
  • now $8.19 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $8.2 (+0.2%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $7.69$8.72
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $7.15$9.67
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 3,322 windows spanning 2013-06-03 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2014-04-28−45.9%−45.9%+0.3%
2014-04-29−45.7%−46.0%+0.0%
2014-04-23−45.4%−45.4%+0.4%
3 best
2020-03-12+49.4%−0.2%+49.4%
2019-10-25+47.8%−1.8%+47.8%
2020-03-18+47.6%+0.0%+48.0%

3,322 overlapping windows · 2013-06-032026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~14 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
62%
+4.4%
n=13
Feb
54%
+2.5%
n=13
Mar
31%
−2.8%
n=13
Apr
46%
+1.5%
n=13
May
46%
−4.1%
n=13
Jun
38%
−2.2%
n=13
Jul
57%
+2.4%
n=14
Aug
50%
+3.2%
n=14
Sep
36%
−3.5%
n=14
Oct
46%
−1.1%
n=13
Nov
54%
+3.0%
n=13
Dec
46%
+2.1%
n=13

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$9$62026-09-09: 1 insider sale, $1K — Tsur David2026-09-08: 1 insider sale, $1.3M — Tsur David2026-09-07: 1 insider sale, $118K — Tsur David2026-09: 3 open-market sales, $1.5M↑ buys↓ salesdirector Tsur David — Sale on 2026-09-09, filed 2 days after the tradedirector Tsur David — Sale on 2026-09-08, filed 3 days after the tradedirector Tsur David — Sale on 2026-09-07, filed 4 days after the trade
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling
2026-09-09Tsur DaviddirectorSale175 @ $8.26$1K−0.0% of holdingnot yet — horizon still opennot yet — horizon still open430,756Form 4 · filed 2 days after the trade
2026-09-08Tsur DaviddirectorSale162,760 @ $8.26$1.3M−27.4% of holdingnot yet — horizon still opennot yet — horizon still open430,931Form 4 · filed 3 days after the trade
2026-09-07Tsur DaviddirectorSale14,238 @ $8.28$118K−2.3% of holdingnot yet — horizon still opennot yet — horizon still open593,691Form 4 · filed 4 days after the trade

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

297 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-09-02Tsur DaviddirectorOption exercise26,500634,429Form 4
2026-09-02Tsur DaviddirectorOption exercise22,500630,429Form 4
2026-09-02Tsur DaviddirectorWithheld for tax6,406607,929Form 4
2026-09-02Tsur DaviddirectorWithheld for tax2,760607,929Form 4
2026-09-02Brenner YaelofficerOption exercise3,0369,302Form 4
2026-09-02Brenner YaelofficerWithheld for tax8656,266Form 4
2026-09-02Tsur DaviddirectorOption exercise26,5000Form 4
2026-09-02Tsur DaviddirectorOption exercise22,5000Form 4
2026-09-02Brenner YaelofficerOption exercise3,0360Form 4
2026-08-26Brenner YaelofficerOption exercise10,00016,266Form 4
2026-08-26Brenner YaelofficerWithheld for tax2,7766,266Form 4
2026-08-26Brenner YaelofficerOption exercise10,0000Form 4
2026-08-05Asher-Topilsky LilachdirectorAward / grant30,00030,000Form 4
2026-08-05RECANATI LEONdirectorAward / grant30,00030,000Form 4
2026-08-05Botzer UridirectorAward / grant30,00030,000Form 4
2026-08-05Tsur DaviddirectorAward / grant30,00030,000Form 4
2026-08-05Payorski LilachdirectorAward / grant30,00030,000Form 4
2026-08-05ITSHAYEK ASSAFdirectorAward / grant30,00030,000Form 4
2026-08-05Goldwasser KarnitdirectorAward / grant30,00030,000Form 4
2026-08-05Dekel BenjamindirectorAward / grant30,00030,000Form 4
2026-08-05DAVIDI ISHAYdirectorAward / grant30,00030,000Form 4
2026-04-07Brenner YaelofficerAward / grant15,00015,000Form 4
2026-04-07Brenner YaelofficerAward / grant15,00015,000Form 4
2026-04-07Brenner YaelofficerDisposition15,00015,000Form 4
2026-04-07Brenner YaelofficerAward / grant15,00015,000Form 4
2026-04-07Brenner YaelofficerDisposition15,00015,000Form 4
2026-04-07Brenner YaelofficerAward / grant15,00015,000Form 4
2026-04-07Brenner YaelofficerDisposition15,00015,000Form 4
2026-04-07Brenner YaelofficerAward / grant15,00015,000Form 4
2026-04-07Nir EranofficerDisposition22,50022,500Form 4
2026-04-07Nir EranofficerAward / grant22,50022,500Form 4
2026-04-07Nir EranofficerDisposition22,50022,500Form 4
2026-04-07Nir EranofficerAward / grant22,50022,500Form 4
2026-04-07Nir EranofficerDisposition22,50022,500Form 4
2026-04-07Nir EranofficerAward / grant22,50022,500Form 4
2026-04-07Beladev ShavitofficerDisposition15,00015,000Form 4
2026-04-07Brenner YaelofficerDisposition15,00015,000Form 4
2026-04-07Nir EranofficerAward / grant22,50022,500Form 4
2026-04-07Nir EranofficerDisposition22,50022,500Form 4
2026-04-07Nir EranofficerAward / grant22,50022,500Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.